Scarica l'app Stockscreener
27.58
0.40%
0.11
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$27.47
Aprire:
$27.6
Volume 24 ore:
36.93M
Relative Volume:
0.66
Capitalizzazione di mercato:
$156.81B
Reddito:
$62.58B
Utile/perdita netta:
$7.79B
Rapporto P/E:
20.35
EPS:
1.3551
Flusso di cassa netto:
$10.38B
1 W Prestazione:
+1.32%
1M Prestazione:
+9.66%
6M Prestazione:
+9.62%
1 anno Prestazione:
+7.57%
Intervallo 1D:
$27.55
$27.94
Intervallo di 1 settimana:
$26.79
$27.94
Portata 52W:
$20.91
$27.94
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, AZN, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
27.58 | 156.19B | 62.58B | 7.79B | 10.38B | 1.3551 |
|
LLY
Lilly Eli Co
|
1,040.00 | 929.27B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
243.45 | 589.19B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
231.50 | 402.08B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
AZN
Astrazeneca Plc
|
205.55 | 317.06B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
163.10 | 307.56B | 54.72B | 14.02B | 15.32B | 7.1855 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-12 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-02 | Ripresa | Citigroup | Neutral |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
Assetmark Inc. Buys 193,859 Shares of Pfizer Inc. $PFE - MarketBeat
Daiwa Downgrades Pfizer (PFE) to Neutral Following Full-Year 2025 Earnings - Finviz
Pfizer Advances VESPER-5 Obesity and Diabetes Trial, Targeting a Key Growth Market - TipRanks
Fund Update: 753,189 PFIZER (PFE) shares added to THORNBURG INVESTMENT MANAGEMENT INC portfolio - Quiver Quantitative
Is Pfizer Inc. (PFE) One of the Best Medical Research Stocks to Buy According to Hedge Funds? - Insider Monkey
Pfizer Hemophilia And Obesity Updates Add Context To Valuation Debate - simplywall.st
Versor Investments LP Sells 37,800 Shares of Pfizer Inc. $PFE - MarketBeat
Meet the 6.3% Yield Dividend Stock That Could Soar in 2026 - Yahoo Finance
Pfizer (NYSE:PFE) Lowered to "Hold" Rating by Daiwa America - MarketBeat
Meet the 6.3% Yield Dividend Stock That Could Soar in 2026 - The Motley Fool
Pfizer Inc. $PFE Shares Sold by Prospera Financial Services Inc - MarketBeat
Pfizer Inc. $PFE Position Cut by CENTRAL TRUST Co - MarketBeat
Illinois Municipal Retirement Fund Cuts Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer (PFE) Sees Mixed Options Sentiment Amid Stock Downgrade - GuruFocus
Glioblastoma Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | InovioPharma, Pfizer, Roche, ACADIA Pharma, BioNTech, Oncotelic Therapeutics - Barchart.com
Varma Mutual Pension Insurance Co Purchases 82,500 Shares of Pfizer Inc. $PFE - MarketBeat
ING Groep NV Lowers Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Purchased by LSV Asset Management - MarketBeat
Pfizer (NYSE:PFE) Cut to Neutral at Daiwa Securities Group - MarketBeat
Here Are Thursday’s Top Wall Street Analyst Research Calls: BP Plc., Borg Warner, Generac, Kraft-Heinz, MercadoLibre, Pfizer, Shopify, Valvoline, and More - 24/7 Wall St.
Madison Asset Management LLC Has $6.17 Million Stock Position in Pfizer Inc. $PFE - MarketBeat
Pfizer Shares Hit Annual Peak on Regulatory and Strategic Momentum - AD HOC NEWS
Analyst recommendations: Pfizer, Applovin, Biogen, Hilton, Snap… - marketscreener.com
Caprock Group LLC Makes New Investment in Pfizer Inc. $PFE - MarketBeat
Daiwa Securities Downgrades Pfizer to Neutral From Outperform, Price Target is $27 - marketscreener.com
Pfizer Hemophilia And Obesity Updates Reshape Growth And Valuation Outlook - Yahoo! Finance Canada
Pfizer, SEC Reach $29M Deal In Insider Trading Fund Dispute - Law360
Pfizer: A Great Opportunity Post Earnings (NYSE:PFE) - Seeking Alpha
Pfizer, SEC Reach $29M End to Scrap Over Insider Trading Settlement - Law.com
Pfizer Balances New Therapies And Pricing With Fresh Biotech Partnerships - simplywall.st
Is Now the Best Time to Buy Pfizer Stock? - The Globe and Mail
Pfizer Reports Strong Earnings OutlookUnusual Call Options Activity Shows Investors are Bullish - Yahoo Finance
Pfizer (PFE) Closes 2025 on Solid Note, Returns $9.8B to Shareholders - Finviz
Can Pfizer's New & Acquired Drugs Offset Its Looming Patent Cliff? - The Globe and Mail
Is Pfizer Stock Now A Value Trap? - Forbes
Wealthfront Advisers LLC Has $14.76 Million Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Sold by Oppenheimer Asset Management Inc. - MarketBeat
Enzyme Inhibitors Market Is Going to Boom |• Pfizer • Merck & Co. - openPR.com
Is Pfizer Stock Heading for a Fall? - Trefis
Pfizer Inc. $PFE Shares Bought by Advisors Asset Management Inc. - MarketBeat
Can Pfizer Stock Withstand These Pressures? - Trefis
Pfizer Gets $29 Million of SAC Capital Insider Trade SEC Payout - Bloomberg Law News
Pfizer (NYSE:PFE) Shares Up 2.1%Still a Buy? - MarketBeat
Pfizer (NYSE:PFE) Sets New 1-Year HighStill a Buy? - MarketBeat
Pfizer stock hits 52-week high at 27.7 USD - Investing.com
Pfizer stock jumps as PFE taps a Swiss biotech incubator — here’s what Wall Street is watching next - Bez Kabli
Smart Money Is Betting Big In PFE Options - Benzinga
Pfizer Inc. (PFE) is a trending stock: Facts to know before betting on it - MSN
Pfizer Inc. (PFE) Announces FDA’s Grant of Priority Review for HYMPAVZI® (marstacimab) sBLA - Yahoo Finance
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Pfizer Becomes Newest Partner Added to BaseLaunch's Biotech Venture Incubator - Yahoo Finance
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):